MVMariya I. Volkova

Mariya I. Volkova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariya I. Volkova has a total of 382 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of four regimens of intravesical BCG therapy in patients with non-muscle-invasive bladder cancer: second interim analysis of a randomized phase II trial

    by Mariya I. Volkova, Волкова Мария Игоревна, Ya. V. Gridneva, Гриднева Я. В., A. Sh. Baymashev, Баймашев А. Ш., O. R. Sinitsyna, Синицына О. Р., A. V. Oskarev, Оскарев А. В., et al.

    The objective of the study was to demonstrate the non-inferiority of low-intensity BCG therapy regimens (BCG – Bacillus Calmette–Guérin) compared with the classical Southwest Oncology Group (SWOG) regimen in patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) who underwent transurethral resection of the bladder tumor (TURBT). Materials and methods. A prospective, interventional, four-arm, open-label, randomized phase II clinical trial with a non-inferiority design is being conducted. The main inclusion criteria are histologically verified intermediate- or high-risk NMIBC in patients aged ≥18 years who have undergone TURBT. Patients were randomized into four treatment groups at a 1:1:1:1 ratio to receive intravesical BCG vaccine therapy: experimental groups 1 (50 mg, 1 year), 2 (50 mg, 3 years), and 3 (100 mg, 1 year), and control group 4 (100 mg, 3 years). The primary endpoint is the 1-year rate of local NMIBC recurrence after TURBT. To confirm the non-inferiority of the studied regimens compared with standard treatment, enrollment of 315 patients is required so that the upper limit of the 99 % one-sided confidence interval (CI) for the hazard ratio (HR) of the 1-year local recurrence rate does not exceed 1.35. Results. A second interim analysis was performed at a median follow-up of 16.7 (2.5–33.6) months. Data from 401 patients with a median age of 66.4 (31–95) years were included. According to the European Organization for Research and Treatment of Cancer (EORTC) risk classification, 93 (23.2 %) patients were classified as intermediate risk and 308 (76.8 %) as high risk. All patients received BCG therapy in the regimen corresponding to their randomization group (group 1 – 100 (24.9 %), group 2 – 92 (23.0 %), group 3 – 109 (27.2 %), group 4 – 100 (24.9 %)). The treatment groups were balanced with respect to the main characteristics. The 1-year local recurrence rate was 12.5 %. At a data maturity of 69.5 % by follow-up duration for the primary endpoint, per-protocol analysis demonstrated non-inferiority of the studied regimens in group 1 (HR 1.029; 99 % CI 0.916–1.156) and group 2 (HR 1.114; 99 % CI 0.850–1.125); the HR between groups 3 vs. 4 was 0.813 (99 % CI 0.349–1.893), in favor of the studied regimen. Conclusion. Short-term results support continuation of the randomized phase II clinical trial until the final analysis of the primary endpoint.

  • Open Access

    The principle of "discretion" and its application in oncology during surgical treatment in accordance with clinical guidelines: law enforcement practice

    by Nikolai A. Ognerubov, Arif K. Allakhverdiev, Lali G. Babicheva, Maria I. Volkova, Rostislav I. Knyazev, Irina V. Kolyadina, Vladimir K. Lyadov, Sergey N. Nered, Sergey O. Podvyaznikov, Igor V. Sagaydak, et al.

    Background. This article presents a thorough medical and legal examination of the principle of "discretion" in the surgical management of malignancies. The significance of this study arises from the mandatory implementation of clinical guidelines effective January 1, 2022, in accordance with Article 37 of Federal Law No. 323-ФЗ. This legislation has notably restricted the scope for individualized medical decision-making. At the same time, the complete algorithmization of surgical oncology remains fundamentally impossible due to the unique features of each clinical case. The authors interpret medical discretion as a specific form of administrative discretion – a legally conferred right enabling physicians to make informed and independent decisions based on clinical circumstances, evidence-based data, and the overarching principle of safeguarding the patient's health. Aim. To provide a comprehensive medical and legal analysis of the "discretion" principle within the surgical phase of cancer treatment, including examining its legal boundaries, its relationship with clinical guidelines, and the notion of informed voluntary consent, as well as an assessment of relevant law enforcement practices. Materials and methods. The study used system analysis, formal legal analysis, comparative law, and content analysis of judicial rulings. A total of 87 judicial decisions about civil cases from 2018 to 2025, relevant regulatory frameworks, and clinical guidelines issued by the Ministry of Health of Russia, the Association of Oncologists of Russia, the Russian Society of Clinical Oncology (RUSSCO), as well as NCCN and ESMO guidelines, along with the 8th edition of the TNM classification of malignant tumors, were reviewed. Results. The findings indicate that discrepancies in clinical and pathomorphological staging, which may reach up to 23.9% in colorectal cancer, render intraoperative approach adjustments a necessary practice. Analysis of specific court cases revealed that the legitimacy of extending the surgical intervention is evaluated not by the outcome but by the appropriateness of the surgeon's actions at the time they were performed, based on the intrinsic connection between surgical practices and pathological morphology, thereby facilitating a clear distinction in responsibility between surgery and pathology teams. Particular importance is attached to informed voluntary consent; it is the substance and completeness of this consent – rather than the mere availability of the document itself – that serves as the decisive mechanism for risk allocation. Conclusion. The authors establish criteria for the legality of extending the surgical intervention and advocate for enhancements to clinical guidelines, the format of informed voluntary consent, surgical protocols, the introduction of a standard for the "reasonable surgeon," and the legislative endorsement of the concept of "reasonable medical risk."

  • Open Access

    Predictive role of peripheral blood erythroblasts for treatment intensification in metastatic hormone-sensitive prostate cancer. A retrospective study

    by Olesia A. Stativko, Стативко Олеся Алексеевна, Irina A. Shangina, Шангина Ирина Александровна, Nikita M. Starostin, Старостин Никита Максимович, Ilya A. Pokataev, Покатаев Илья Анатольевич, Alexey A. Rumyantsev, Румянцев Алексей Александрович, et al.

    Aim. To investigate the predictive value of baseline erythroblasts in selecting patients with metastatic hormone-sensitive prostate cancer (mHSPC) for triplet therapy. Materials and methods. We provided a multicenter retrospective study that included patients treated between 2022 and 2024 for high-volume mHSPC according to CHAARTED criteria who received either doublet [androgen deprivation therapy (ADT) + an androgen receptor pathway inhibitor (ARPI)] or triplet (docetaxel + ADT + ARPI) therapy. The primary endpoint was 2-year progression-free survival (PFS), defined as time from treatment initiation to clinical or radiological progression, initiation of new systemic therapy, or death from any cause. Cardinality matching at a 2:1 ratio was performed to balance potential confounding variables. Results. A total of 234 patients were included (141 triplet, 93 doublet). After matching, 122 patients remained in the triplet group and 61 in the doublet group. With a median follow-up of 23.5 months for the triplet group and 33.9 months for the doublet group, 2-year PFS rates were 71.9 and 57.8%, respectively (HR 0.62, 95% CI 0.40–0.95; p=0.027). Subgroup analysis demonstrated significantly greater survival benefit from triplet therapy in patients with detectable baseline erythroblasts (PFS: HR 0.29, 95% CI 0.11–0.76; OS: HR 0.24, 95% CI 0.07–0.77) compared to those without erythroblasts (PFS: HR 0.66, 95% CI 0.37–1.19; OS: HR 0.52, 95% CI 0.26–1.06). Conclusion. The baseline presence of circulating erythroblasts serves as a strong predictive marker for benefit from docetaxel intensification in patients with high-volume mHSPC. This readily available biomarker may guide patient selection for triplet therapy, pending prospective validation.

  • Open Access

    Safety of four intravesical BCG therapy regimens in patients with non-muscle-invasive bladder cancer: second interim analysis of a phase II randomized trial

    by Maria I. Volkova, Yana V. Gridneva, Artur Sh. Baimashev, Ogulshat R. Sinitsyna, Albert V. Oskarev, Olesia A. Stativko, Ilya A. Pokataev, Elizaveta M. Koldakova, Vitalii А. Cherniaev, Georgy M. Mushukya, et al.

    Aim. To evaluate the safety of four regimens of Bacillus Calmette-Guérin (BCG) therapy following transurethral bladder resection in patients diagnosed with intermediate- and high-risk non-muscle-invasive bladder cancer. Materials and methods. This study is a prospective, interventional, four-arm, open-label, randomized phase II clinical trial with a non-inferiority design. The main inclusion criteria were histologically confirmed non-muscle-invasive bladder cancer of intermediate or high risk in patients aged 18 years or older who have undergone transurethral resection of the bladder. Participants were randomized into four treatment groups in a 1:1:1:1 ratio for intravesical therapy utilizing the BCG vaccine: test groups 1 (50 mg, 1 year), 2 (50 mg, 3 years), 3 (100 mg, 1 year), and a control group 4 (100 mg, 3 years). The primary endpoint of the randomized controlled trial was the one-year local recurrence rate, while secondary endpoints reported in this publication included safety and toxicity. Results. The second interim analysis, with a median follow-up of 16.7 months (range: 2.5–33.6 months), included data from 401 patients with a median age of 66.4 years (range: 31–95 years). Within the EORTC intermediate-risk group, 93 patients (23.2%) were included, while the high-risk group comprised 308 patients (76.8%). All patients received BCG therapy according to their assigned randomization group: group 1 – 100 patients (24.9%); group – 92 patients (23.0%); group 3 – 109 patients (27.2%); group 4 – 100 patients (24.9%). The treatment groups were balanced with respect to the main characteristics. A total of 133 patients (33.2%) and 184 patients (45.9%) required an adjustment in the interval between induction and maintenance instillations, respectively. The induction completion rate was 96.8%, while the maintenance administration rate was 86.0%. Adverse events (AEs) were reported in 363 patients (90.5%), with 40 events (10.0%) reaching grades 3–4, requiring hospitalization in 14 patients (3.5%). The most prevalent local AEs included dysuria (339 patients; 84.5%), hematuria (45 patients; 11.2%), and nonspecific urinary infection (42 patients; 10.5%). Systemic AEs included hyperthermia, affecting 85 patients (21.2%). Tuberculosis was diagnosed in 3 patients (0.7%). The analysis indicated no significant differences in the safety profile or toxicities among the study regimens when compared with the standard regimen. Conclusion. The findings from the second interim safety analysis do not support the hypothesis that the tolerability of the BCG regimen can be enhanced by reducing its intensity.

  • Open Access

    Efficacy and safety of 177Lu-PSMA radioligand therapy: a real-world study

    by M. I. Volkova, O. A. Stativko, O. V. Romanchuk, A. Yu. Markova, I. A. Mazur, O. R. Sinitsyna, A. V. Oskarev, Ya. V. Gridneva, I. A. Pokataev

    Objective : To evaluate the effectiveness and safety of 177 Lu-PSMA radioligand therapy (RLT) in patients with disseminated prostate cancer who were followed up in healthcare institutions of the Moscow Department of Health and received treatment outside of clinical trials. Materials and methods : This retrospective study included patients with disseminated prostate cancer treated with 177 Lu-PSMA RLT and followed up at outpatient oncology centers in Moscow between January 1, 2022, and December 1, 2025. Inclusion criteria: histologically verified prostate adenocarcinoma, radiological signs of metastatic disease, and treatment with at least 1 cycle of 177 Lu-PSMA RLT. Exclusion criteria: absence of data on ≥ 1 177 Lu-PSMA administration and ≥ 1 follow-up examination after treatment initiation. The primary endpoint was radiologic progression-free survival (rPFS). The secondary endpoints included the PSA50 response rate (defined as a ≥ 50 % decline in prostate-specific antigen from baseline), PSA progression-free survival (PSA-PFS), progression-free survival according to the Prostate Cancer Working Group 3 criteria (PFSPCWG3), overall survival (OS), time to clinical deterioration, safety, and toxicity. Results : A total of 41 patients were included in the analysis. The median age was 72 years (range: 53–85). At RLT initiation (baseline), 9 patients (21.9 %) had ECOG PS scores of 2–3. Twenty-nine patients (70.7 %) had been previously treated with ≥ 1 taxane and ≥ 1 androgen receptor signaling inhibitor (ARSI). Castration resistance prior to RLT initiation was observed in 40 patients (97.6 %). The median baseline PSA level was 121.7 ng / mL (range: 0.6–4987.7). All patients had PSMA-positive metastases; in 3 cases (7.3 %), these were accompanied by clinically significant PSMA-negative metastases. All patients received 177 Lu-PSMA RLT (median of 4 cycles [range, 1–8]). Forty patients (97.6 %) received RLT concomitantly with continuous androgen deprivation therapy (ADT); 11 patients (26.8 %) received RLT during ADT in combination with an ARSI; 3 patients (7.3 %) underwent combined systemic radiopharmaceutical therapy (2 patients [4.9 %] with 177 Lu-PSMA / 153 Sm, and 1 patient [2.4 %] with 177 Lu-PSMA / 225 Ac-PSMA). The median follow-up duration was 10 months (range: 0.4–30). The PSA50 response rate was 46.3 %, median rPFS was 6.2 months (95 % confidence interval [CI], 4.7–7.7), median PSA-PFS was 5.2 months (95 % CI, 2.7–7.7), median PFSPCWG3 was 5.7 months (95 % CI, 4.8–6.5), median OS was 11.4 months (95 % CI, 6.2–16.6), and median time to clinical deterioration was 5.8 months (95 % CI, 3.9–7.8). Serious AEs were reported in 18 patients (43.9 %), AE-related RLT discontinuation was required in 8 cases (19.5 %), and AE-related death was reported in 3 cases (7.3 %). Grade 3–4 anemia developed in 15 patients (36.6 %), grade 3–4 thrombocytopenia in 14 patients (34.1 %), and neutropenia in 17 patients (41.5 %). Conclusion : Data from real-world clinical practice confirm the effectiveness of 177 Lu-PSMA RLT in patients with disseminated prostate cancer. However, the safety profile raises significant concern. These findings highlight the need for a more balanced approach to patient selection for RLT.

  • Open Access

    Analysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)

    by Ya. V. Gridneva, M. I. Volkova, Yu. V. Anzhiganova, V. S. Bragina, В. А. Водолазский, M. I. Gluzman, R. A. Zukov, A. M. Ivanov, E. R. Israelyan, E. V. Karabina, et al.

    Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.


  • Open Access

    Will darolutamide in double combination become the new standard of treatment for hormone-sensitive prostate cancer?

    by Mariya I. Volkova, K. A. Turupaev

    Darolutamide is a high-affinity second–generation antiandrogen, the effectiveness and favorable safety profile of which have been proven two phase III randomized clinical trials (RCTs) in metastatic hormone-sensitive prostate cancer (mHSPC) as part of a triple combination with docetaxel and androgen deprivation therapy (ADT) (ARASENS), as well as non-metastatic castration-resistant prostate cancer in the composition double combination with ADT (ARAMIS). Positive results have now become available from another phase III RCT ARANOTE, aimed at comparing the efficacy of the double combination of darolutamide with ADT and placebo with ADT in patients with mHSPC. Darolutamide significantly prolonged radiological progression-free survival, reducing the risk of radiological progression or death by 46 % compared with placebo (primary endpoint), also provided benefit of secondary study endpoints, including time to castration resistance and time to pain progression. The clinical benefit of darolutamide in primary and secondary points was realized regardless of the volume of metastatic load. Data on overall survival is immature. The incidence of adverse events was low and similar in the darolutamide and placebo groups, with a lower incidence of fatigue in the darolutamide group. The obtained data on the effectiveness of darolutamide with ADT in mHSPC are comparable with the results of similar studies of other second-generation antiandrogens enzalutamide (ARCHES phase III RCT) and apalutamide (TITAN phase III RCT). Potentially, the combination of ADT with darolutamide could claim a place in the list of standard treatment methods and expand therapeutic options for patients with mHSPC.

  • Open Access

    Radioligand therapy with 177Lu-PSMA in castration-resistant prostate cancer: a literature review and case series

    by Maria I. Volkova, Alexander S. Krylov, Dmitry A. Nosov, Boris Ya. Alekseev

    Overexpression and ligand-dependent internalization of prostate-specific membrane antigen (PSMA), followed by its accumulation in prostate cancer (PCa) cells, make this glycoprotein a good target for radionuclide-based targeted therapy. Currently, the only drug in this group with efficacy proven in a large randomized clinical study in patients with metastatic castration-resistant PCa is 177Lu-PSMA-617. The article presents an overview of the data on the mechanism of action and the results of completed studies of radioligand therapy (RLT) with 177Lu-PSMA for PCa, the current indications for this type of treatment in patients with a castration-resistant phase of the disease, and practical guidelines for RLT, including its planning, implementation, monitoring of effectiveness, and radiation protection measures. Clinical cases of patients with partial response/stabilization of the disease during RLT, significant improvement/complete response, and progression of PCa are presented.

  • Open Access

    Comparative analysis of the mutational status of non-muscle-invasive and muscle-invasive urothelial carcinoma

    by Maria I. Volkova, Darya N. Khmelkova, Yana V. Gridneva, Konstantin A. Blagodatskikh, Anna A. Zheludkevich, Irina V. Mironova, Anna B. Semenova, Alexander A. Veshchevailov, Alexandra V. Babkina, Sergey A. Bondarev, et al.

    Aim. To identify mutational profile differences of non-muscle-invasive (NMIUC) and muscle-invasive urothelial carcinoma (MIUC) of the bladder, assessed through isolating alterations in deoxyribonucleic (DNA) and ribonucleic (RNA) acids by a next-generation sequencing (NGS) method using a panel of 523 genes. Materials and methods. Tumor tissue and medical data of 72 patients with histologically confirmed bladder UC were studied. NMIUC was diagnosed in 40 (55.6%) patients, and MIUC in 32 (44.4%) patients. In 25 (34.7%) samples the tumor grade was assessed as low: 24 (33.3%) with NMIUC and 1 (1.4%) with MIUC, and in 47 (65.3%) as high: 16 (22.2%) with NMIUC, 31 (43.1%) with MIUC. In isolated tumor cells DNA and RNA alterations were detected by NGS using a panel of 523 genes. Results. NMIUC, compared to MIUC, was characterized by a lower median mutational burden (9.9 mut/Mb vs. 11.8 mut/Mb, respectively; p=0.037) and was associated with a higher rate of mutations of the FGFR/FGF (p=0.059) and STAG2/IRF (p=0.055) signaling pathways genes, as well as the FGFR3 (p=0.001) and STAG2 (p=0.026) genes with a lower rate of aberrations of the p53 signaling pathway genes (p=0.005), TP53 (p=0.001) and FGF4 (p=0.057). The low grade NMIUC samples had a lower rate of high mutational burden (vs. high grade NMIUC, p=0.004; vs high grade MIUC, p=0.067) and were also associated with a higher rate of FGF/FGFR signaling pathway gene mutations (vs. high grade MIUC, p0.0001; vs. high grade NMIUC, p0.0001), mainly due to FGFR3 alterations (vs. high grade NMIUC; p0.0001; vs. high grade MIUC; p0.0001). Low grade NMIUC, compared to high grade MIUC, had a higher rate of PIK3CA (p=0.027) and KDM6A (p=0.001) mutations. The mutational profile of high grade NMIUC and high grade MIUC did not differ significantly. High grade MIUC, compared to low grade NMIUC had a higher rate of mutations of the p53 pathway genes (p=0.008), including TP53 (p=0.001), and a significantly lower rate of alterations of the FGF/FGFR signal pathway genes (p0.0001), including FGFR3 (p0.0001), as well as the STAG2/IRF pathway genes (p=0.035) and the PIK3CA gene (p=0.027). Conclusion. Differences of the histological structure and natural history of low grade NMIUC, high grade NMIUC, and high grade MIUC are due to significant differences in their mutational status. NMIUC has a high rate of mutations in genes of the FGF/FGFR signaling pathway and inactivating mutations in STAG2 and KDM6A genes. MIUC typically has driver mutations that inactivate the p53 signal pathway. High grade NMIUC has alterations typical for both NMIUC (FGF/FGFR pathway gene mutations) and MIUC (p53 pathway gene mutations).

  • Open Access

    Prostate cancer with regional lymph node involvement: Is there a universal solution?

    by M. I. Volkova, I. S. Al-Akel

    Population of the patients with prostate cancer N1M0 is heterogenous, and their treatment requires the use of risk-adapted approach. In case of clinically positive lymph nodes (cN1): choice option: external beam radiation therapy (EBRT) with long-term adjuvant androgen deprivation therapy (ADT) (36 months) and abiraterone with prednisolone (24 months); alternative: radical prostatectomy (in case of 1–2 enlarged regional lymph nodes and ISUP (International Society of Urological Pathology) grade 1–3) with possible subsequent prescription of ADT with or without EBRT depending on the presence of risk factors; in case of short life expectancy: immediate ADT in combination with abiraterone acetate and prednisolone or delayed ADT (depending on the presence of symptoms and expected duration of survival). In cases of histologically verified metastases in the regional lymph nodes (pN1): choice option: immediate constant lifetime adjuvant ADT; alternative if postoperative prostate-specific antigen level 0.1 ng/mL or 3 positive lymph nodes: dynamic observation; alternative in the presence of risk factors (category pT ≥T3b, Gleason score 9–10, R1) and ≥3 positive lymph nodes: adjuvant EBRT and ADT. Development of the optimal risk-adapted approach requires well-planned randomized clinical trials with adequate stratification and endpoints using high-fidelity diagnostic techniques, modern EBRT methods and new antitumor drugs.